CAS: 848318-25-2 - SSR128129E
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
FGFR inhibitor REF: IN-DA00G3PXCAS: 848318-25-2 | 98% | 96.00 €~602.00 € | Tue 07 Jan 25 | |
SSR128129E REF: TM-T6082CAS: 848318-25-2 | 98.79% - ≥95% | 40.00 €~432.00 € | Mon 13 Jan 25 | |
SSR128129E REF: 10-F468370CAS: 848318-25-2 | 95.0% | To inquire | Tue 14 Jan 25 | |
SSR128129E REF: TR-S684470CAS: 848318-25-2 | - - - | 200.00 €~1,323.00 € | Tue 14 Jan 25 | |
SSR128129E REF: 3D-FS137720CAS: 848318-25-2 | Min. 95% | - - - | Discontinued product |
FGFR inhibitor
CAS:848318-25-2
Formula:
C18H15N2NaO4
Purity:
98%
Color and Shape:
Solid
Molecular weight:
346.3125
Ref: IN-DA00G3PX
25mg | 119.00 € | ||
50mg | 198.00 € | ||
100mg | 240.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
SSR128129E
CAS:848318-25-2
SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting …
Formula:
C18H15N2O4·Na
Purity:
98.79% - ≥95%
Color and Shape:
Solid
Molecular weight:
346.31
Ref: TM-T6082
2mg | 40.00 € | ||
5mg | 61.00 € | ||
10mg | 88.00 € | ||
25mg | 155.00 € | ||
50mg | 275.00 € | ||
100mg | 432.00 € | ||
1mL*10mM (DMSO) | 77.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025
Ref: 10-F468370
1mg | To inquire | ||
5mg | To inquire | ||
10mg | To inquire |
Estimated delivery in United States, on Tuesday 14 Jan 2025
SSR128129E
Controlled ProductCAS:848318-25-2
Applications SSR128129E (SSR) is an potent FGFR inhibitor, which inhibits fibroblast growth factor receptor (FGFR). …
Formula:
C18H15N2NaO4
Color and Shape:
Yellowish Solid
Molecular weight:
346.31
Ref: TR-S684470
5mg | 200.00 € | ||
25mg | 422.00 € | ||
100mg | 1,323.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
SSR128129E
CAS:848318-25-2
SSR128129E is a monoclonal antibody that has been shown to inhibit the tyrosine kinase domain …
Purity:
Min. 95%
Ref: 3D-FS137720
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information |